IL1A and TNF receptor 1-associated periodic fever syndrome: Indeed, initial anecdotal reports on promising use of anti-IL1 agents have been followed by the Eurofever Registry data (45), international expert consensus reports (46) and eventually a placebo-controlled, randomised study of canakinumab (39) proving IL-1 blockade as a safe and effective therapy for TRAPS, emphasising the pivotal role of IL-1 in the pathogenesis.